BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29120508)

  • 1. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
    Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.
    Palitzsch B; Hartmann S; Stergiou N; Glaffig M; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2014 Dec; 53(51):14245-9. PubMed ID: 25318465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
    Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
    Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 7. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
    Gaidzik N; Westerlind U; Kunz H
    Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
    Sarkar S; Salyer AC; Wall KA; Sucheck SJ
    Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
    Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
    Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
    Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
    Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.
    Thompson P; Lakshminarayanan V; Supekar NT; Bradley JM; Cohen PA; Wolfert MA; Gendler SJ; Boons GJ
    Chem Commun (Camb); 2015 Jun; 51(50):10214-7. PubMed ID: 26022217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
    Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.